Please assess the completion status of the following clinical trial:

Trial Title: Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* The patient should accomplish all the criteria to proceed to an allogeneic transplant~* The patient or their legal guardians should signed the informed consent approved by the Ethics Committees of Clinical Trials~Exclusion Criteria:~* Hypercalcemia ≥ 10.5 mg/dl~* Renal insufficiency with creatinine level ≥ 2 x upper limit of normal (1,1 mg/dl)~* Participation in others Clinical Trials in which the intervention may affect the result of the study.~* Patients receiving GVHD immunoprophylaxis with thymoglobuline or GVHD prophylaxis including in vitro or in vivo lymphocytes T depletion (anti-lymphocyte T globulin, ALG)~* Patients receiving a transplant from an haploidentical donor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Control (Type: NO_INTERVENTION): Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
- Group 2: 1000IU/day of Vitamine D (Type: EXPERIMENTAL): It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
- Group 3: 5000IU/day of Vitamine D (Type: EXPERIMENTAL): It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).